Type 2 Diabetes

A secondary analysis of the D2d study provides evidence suggesting vitamin D supplementation in patients with prediabetes provided no significant benefit on kidney outcomes from within the study.

Patients with metabolic syndrome were at a 46% increased risk of a second stroke and a 27% increased risk of mortality when compared to their counterparts without metabolic syndrome.

The final portion of our 3-part series on insulin affordability in 2021, a clinical pharmacy specialist and a nurse practitioner discuss how recent developments impact the cost of insulin and whether "Insulin for All" is a meaningful phrase or wishful thinking.

A clinical pharmacist and nurse practitioner offer perspective on how the interchangeable biosimilar approval of Semglee impacts discussions around the cost of insulin for patients with diabetes and what they think is important for patients, providers, and pharmacists to know about the historic FDA approval.

Diana Isaacs, PharmD, a clinical pharmacy specialist, and Lucia Novak, CRNP, a nurse practitioner, have a discussion centered around how Walmart's recent launch of ReliOn NovoLog impacts the landscape of diabetes management and insulin affordability.

Titled, "Insulin for All? How Recent Developments Impact Insulin Affordability," this 3-part video series from Diana Isaacs, PharmD, and Lucia Novak, CRNP, explores how news from Walmart and Novo Nordisk and a historic approval from the US FDA impacts insulin affordability with the backdrop of the 100-year anniversary of the discovery of insulin.

Abbott announced the FDA's clearance of their FreeStyle Libre 2 iOS app, which the company suggests is the only sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone every minute with optional real-time glucose alarms, in a release on Aug. 2.

Our latest emergency department case report from Brady Pregerson, MD, features a woman in her 60s with a history of diabetes presenting for post-menopausal vaginal bleeding. Can you determine the correct diagnosis?

The app will deliver up-to-the-minute glucose data in patients using Freestyle Libre 2 glucose sensors.

July's month in review features stories related to new diabetes medications, National Kidney Foundation guidance, and FDA news. Check back in during the last weekend of each month for the next Endocrine Month in Review.

Using data from the National Health Interview Survey, investigators determined patients with diabetes in high deductible health plans were 28% more likely than those in traditional health plans to report cost-related medication non-adherence and this gap only widened when examining insulin users.

Higher microbiome α diversity had an association with less T2D and lower insulin resistance in individuals without diabetes.

Data show no clinically meaningful difference between insulin glargine-yfgn and insulin glargine in matters of safety, purity and potency.

Announced on July 28, insulin glargine-yfgn (Semglee) becomes the first interchange biosimilar insulin product to receive approval in the FDA's history and is expected to be available by the end of the year.

Data show dapagliflozin was projected to add 0.63 quality-adjusted life-years at an incremental lifetime cost of $42, 800.

An analysis of a subset of patients from the STAMPEDE trial provides new evidence detailing the quality of life improvements associated with undergoing bariatric surgery in patients with uncontrolled type 2 diabetes.

A cross-sectional analysis of data from the National Center for Health Statistics indicates the presence of 4 cardiovascular risk factors prior to becoming pregnant can help identify pregnancies at increased risk of adverse fetal or maternal outcomes.

Harold Bays, MD discussed the effectiveness of GLP-1 RA in treatment, as well as the development of oral semaglutide.

With approval, exenatide extended-release (BYDUREON BCise) becomes the first weekly GLP-1 RA therapy to receive approval for improving glycemic control in pediatric patients aged 10-17 years with type 2 diabetes.

Exenatide extended-release represents the first regulatory approval for a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) for pediatric patients with type 2 diabetes.

Data show while women with GDM wanted to be responsible for their own health, an annual reminder and combined appointments would help to screen for T2D.

A prespecified analysis of patients with stage 4 CKD from DAPA-CKD suggests the magnitude of effects seen with dapagliflozin use among these patients was similar to that seen among patients with normal to moderately impaired kidney function from the trial.

With approval announced on July 19, HFX becomes the only spinal cord stimulation therapy approved by the FDA with a specific indication for painful diabetic neuropathy.

Thought leaders in diabetes provide closing remarks about the importance of continuous awareness of glycemic control in patients as well as the need for effective communication between patients and providers. 

A panel of experts in the treatment of diabetes discusses the importance of self-management of blood glucose levels and emphasizes the need for multidisciplinary care teams and referrals for optimal disease management.